Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: A Case Report and a Review of the Literature

Kuraishi, Natsuki; Nagai, Yayoi; Hasegawa, Michiko; Ishikawa, Osamu

doi:10.2340/00015555-0758

Cited by 48 publications

(44 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lichenoid eruptions have been reported rarely but typically resemble LP of the skin and/or oral mucosa without the follicular involvement seen in our cases. Additionally, these eruptions from imatinib contain dense lichenoid infiltrates on histology, which is also not a feature of our cases [8]. …”

Section: Commentmentioning

confidence: 99%

Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

et al. 2015

View full text Add to dashboard Cite

Background: Recently developed tyrosine kinase inhibitors (TKIs) offer first-line alternatives to patients with chronic myeloid leukemia. While these medications are generally well tolerated, cutaneous reactions occur frequently and can present a management challenge. We describe a newly recognized skin reaction to dasatinib and nilotinib and extend it to the newer agent ponatinib. Observations: Nine patients developed varying degrees of a clinically and histopathologically lichenoid exanthem comprised of erythematous, predominately follicular papules with scale and alopecia. The pattern is reminiscent of the scarring and nonscarring alopecia of follicular lichen planus/lichen planopilaris (LPP) with keratosis pilaris-like LPP - the rare Graham-Little-Piccardi-Lassueur syndrome. Importantly, the accompanying pruritus can be severe enough to result in discontinuation of therapy. Conclusions: Clinicians should be aware of this unusual eruption to the newer TKIs and the potential therapeutic challenges. Understanding these eruptions may also suggest potential mechanisms in the idiopathic forms of follicular lichen planus.

show abstract

Section: Commentmentioning

confidence: 99%

Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The skin lesions improved after discontinuation of imatinib mesylate but re-administration of the drug at a lower dose provoked a mild recurrence but skin lesions were well-controlled by topical corticosteroid treatment [31]. …”

Section: Resultsmentioning

confidence: 99%

Treatment modalities of palmoplantar lichen planus: a brief review

Feily¹,

Yaghoobi²,

Nilforoushzadeh³

2016

pdia

View full text Add to dashboard Cite

Palmoplantar lichen planus is a localized and uncommon variant of lichen planus which is mostly resistant to treatment. Our purpose was to discuss all treatment modalities proposed and tested for palmoplantar lichen planus in the literature. A systematic review of the literature was conducted to evaluate evidence regarding all treatment modalities proposed and tested for palmoplantar lichen planus in the literature. Two major databases (PubMed, Google scholar) were searched. The review included all case reports, letters and original articles reporting any treatment for palmoplantar lichen planus but not treatment used in the other type of lichen planus, generalized lichen planus or other type of palmoplantar dermatoses. We have gone over more than 50 articles. There are many drugs that have been used in the treatment of lichen planus and generalized lichen planus but the palmoplantar type is a rare variety of lichen planus. That is why we could not find any clinical trial on the subject and just case reports have been described in this manuscript. In spite of plentiful investigations carried out on lichen planus, there is no treatment modality that has proved to be utterly satisfactory in treatment of palmoplantar lichen planus.

show abstract

“…İnhibitör aktivitesi bcr-abl, stem cell factor receptor (c-KIT) ve platelet derived growth factor receptor (PDGFR)'ne karşıdır 4 . PDGFR ve c-KIT'in epidermal homeostazis üzerinde etkisi olduğu ve epidermal inflamasyonu başlattıkları yakın zamanda yapılan çalışmalarda gösterilmiştir 5 . İmatinibe bağlı gözlenen kutanöz yan etkiler imatinibin nonhematolojik yan etkileri arasında en sık görüleni olup %17-38 oranında gözlenir 6 .…”

Section: Discussionunclassified

Imatinib ile indüklenen eritrodermi olgusu

Bulur¹,

Saraçoğlu²,

Böyük³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

Türk derm-De ri Has ta lık la rı ve Fren gi Ar şi vi Der gi si, Ga le nos Ya yı ne vi ta ra f›n dan ba s›l m›fl t›r. Turk derm-Arc hi ves of the Tur kish Der ma to logy and Ve ne ro logy, pub lis hed by Ga le nos Pub lis hing. Özetİmatinib kronik myeloid lösemi (KML) tedavisinde kullanılan ilk moleküler hedeflenmiş ilaçtır. İmatinibin indüklediği advers kutanöz reaksiyonlar sıktır ve genellikle orta şiddetlidir. Diğer taraftan imatinib ile indüklenen eritrodermi nadir olarak gözlenir ve literatürde sadece birkaç olgu yer almaktadır. Bu yayında KML hastasında imatinibin indüklediği eritrodermi olgusu sunulmaktadır. (Türk derm 2014; 48: 54-6) Anah tar Ke li me ler: İmatinib, eritrodermi, deri reaksiyonları Sum maryImatinib is the first molecularly targeted drug developed for the treatment of chronic myeloid leukemia (CML). Adverse cutaneous reactions induced by imatinib are frequent and generally moderate. On the other hand, imatinib-induced erythroderma is an uncommon reaction, and only a few cases have been reported in the literature. In this paper, we report a case of erythrodermia induced by imatinib in a patient with CML. ( OlguYetmiş iki yaşında erkek hasta kliniğimize yüzde şişlik ve vücutta yaygın kızarıklık nedeniyle başvurdu. Hastanın öyküsünden şikayetlerinin ilk kez iki hafta önce yüzde özellikle göz kapakları çevresinde şişlik ile başladığı, birkaç gün sonra da tüm vücutta yaygın kızarıklık geliştiği öğrenildi. Hasta diyabetes mellitus, koroner arter hastalığı nedeni ile uzun süredir repaglinid, metformin, quinapril, asitsalisilik asit aldığını ve son altı haftadır da KML tanısı ile 400 mg/gün imatinib kullandığını belirtti. Hastanın dermatolojik muayenesinde tüm vücutta şiddetli kaşıntının eşlik ettiği yüzde ödem, yaygın eritem, deskuamasyon, bilateral el palmar bölgede ve ayak plantar

show abstract

Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: A Case Report and a Review of the Literature

Cited by 48 publications

References 8 publications

Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Treatment modalities of palmoplantar lichen planus: a brief review

Imatinib ile indüklenen eritrodermi olgusu

Contact Info

Product

Resources

About